Zamira Australia has raised US$5.4 million to fund Companion Animal’s growth initiatives
Zamira Australia has completed a fundraising to support Companion Animal’s growth initiatives and further strengthen its balance sheet.
Zamira is an Australian animal health brand whose mission is to improve the health and well-being of animals across the world. The company is favorably positioned as a premium brand, with localized understanding and expertise – a trusted and strong Australian brand identity amongst its international competitors. The Companion Animal range is Zamira’s new line of Australian-made premium supplements for pets. Formulated by Australian vets using ethically sourced ingredients, ZamiPet helps support digestive and immune function, maintain vitality, joint health, cognitive function, skin, coat and nails, as well as helping support the reduction of stress, tension and anxiety in dogs.
Oaklins’ team in Australia acted as corporate advisor and lead manager to the raise and continues to support Zamira as they strive to become a leader in pet health and well-being, and a global leader in the supply of animal health products.
Talk to the deal team
Related deals
Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider
Holland Capital, a Netherlands-based private equity firm, has acquired a stake in Top Systems, a leading provider of complete battery-based power solutions, with a unique value-added services proposition.
Learn moreInfotreasury has been sold to Matera
Matera, a leading banking software company with world-class instant payments and core banking solutions, has acquired Infotreasury.
Learn moreThrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH
Paradiesfrucht GmbH, a gobal freeze dryer of fruits, fruit preparations, drops, powders and granulates, has been acquired by Thrive Freeze Dry (Thrive), a portfolio company of Entrepreneurial Equity Partners (e2p) and Mubadala Capital. The transaction is expected to close in 2024, subject to customary closing conditions, including antitrust approval.
Learn more